

April-1996

[AK 157]

M.D. DEGREE EXAMINATION.

Branch IX — Radiotherapy

(Revised Regulations)

Part II — Final

Paper III — CANCER CHEMOTHERAPY AND RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY
AND RADIOTHERAPY

Time : Three hours

Maximum : 100 marks

Answer ALL questions.

1. "Stereotactic Radiotherapy" Discuss in detail the technique and its clinical significance. (25)
 2. Discuss the dependence of the effects of chemotherapeutic agents upon cells in the cycle and its constituent phases. (26)
 3. Write briefly on : (5 × 16 = 80)
 - (a) Total body irradiation.
 - (b) Continuous Hyperfractionated Accelerated Radiotherapy (CHART).
 - (c) Aminoglutethamide.
 - (d) National cancer control programme.
 - (e) L.Q. model in Radiotherapy.
-

M.D. DEGREE EXAMINATION
Branch IX - Radio Therapy
(Revised Regulations)
Part II - Final

Paper III - CANCER CHEMOTHERAPY & RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY
& RADIOTHERAPY

Time: Three hours

Max.marks:100

Answer All Questions

1. Discuss the applications and role of Monoclonal antibodies in neoplastic disorders. (25)
2. The management of soft tissue sarcoma is still controversial. Discuss the role of Radiotherapy and cytotoxic drugs. (25)
- 3 Write briefly on:
 - (a) Oncogenes
 - (b) Hyperthermia
 - (c) Hemibody irradiation
 - (d) Tumour lysis syndrome
 - (e) Radioactive phosphorous-32.

(5x10=50)

April-1997

MP 148

M.D. DEGREE EXAMINATION

Branch IX - Radio Therapy

(Revised Regulations)

Part II - Final

Paper III - CANCER CHEMOTHERAPY & RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY &
RADIOTHERAPY

Time: Three hours

Max.marks:100

Answer All Questions

1. Describe the present classification of malignant lymphomas. Discuss the role of radiotherapy and chemotherapy. (25)
2. Describe the modern trends in aetiology and diagnosis of cancer breast and the role of radiation in its management. (25)
3. Write briefly on:
 - (a) Hyperthermia
 - (b) Radioactive Iodine
 - (c) Immunotherapy
 - (d) Betatracer
 - (e) Iridium 192.

(5x10=50)

October-1997

MS 148

M.D. DEGREE EXAMINATION

Branch IX - Radio Therapy

(Revised Regulations)

Part II - Final

Paper III - CANCER CHEMOTHERAPY & RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY AND
RADIOTHERAPY

Time: Three hours

Max.marks:100

Answer All Questions

1. Describe the various diseases where cancer chemotherapy is best compared to Radiation and surgery. (25)
2. Describe the various radiation techniques in management of ovarian malignancies. (25)
3. Write briefly on:
 - (a) Negative pi-mesons
 - (b) Paraneoplastic syndromes
 - (c) Role of genetics in cancer
 - (d) Radioactive gold
 - (e) Mycosis fungoide:

(5x10=50)

April-1998

SV 15:

M.D. DEGREE EXAMINATION

Branch IX - Radio Therapy

(Revised Regulations)

Part II - Final

**Paper III - CANCER CHEMOTHERAPY & RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY
& RADIO THERAPY**

Time: Three hours

Max. marks: 100

Answer All Questions

1. Discuss the pathological classification and staging of carcinoma bronchus. Discuss the role of chemotherapy and radiation therapy in the management of small cell carcinoma lung. (25)
2. How will you investigate a case of Hodgkin's disease? Discuss the role of radiotherapy and chemotherapy in the treatment of this disease. (25)
3. Write briefly on:
 - (a) Stereotactic radiotherapy
 - (b) Endobronchial irradiation
 - (c) I.D. Model in Radiotherapy
 - (d) Altered fractionation regimens
 - (e) Newer radio isotopes in radiotherapy.

(5x10=50)

October-1998

[SM 155]

M.D. DEGREE EXAMINATION.

Branch IX — Radio-Therapy

(Revised Regulations)

Part II — Final

**Paper III — CANCER CHEMOTHERAPY AND RECENT
DEVELOPMENTS IN CLINICAL ONCOLOGY AND
RADIOTHERAPY**

Time : Three hours

Maximum : 100 marks

Answer ALL questions.

1. Describe the rationale of concurrent Radiotherapy-Chemotherapy Protocols in Head and Neck Cancer. (25)
2. What is Hyperfractionation? In what clinical situations do you practice hyperfractionation schedule? Give Rationale of such treatments. (25)
3. Write briefly on : (5 × 10 = 50)
 - (a) Compensators.
 - (b) Intra-Operative radiotherapy.
 - (c) Electron therapy.
 - (d) Immobilisation devices.
 - (e) Stereotactic Radiotherapy.

[SG 155]

Sub. Code : 2087

M.D. DEGREE EXAMINATION.

Branch IX — Radiotherapy

(Revised Regulations)

Part II — Final

Paper III — CANCER CHEMOTHERAPY AND
RECENT DEVELOPMENTS IN CLINICAL
ONCOLOGY AND RADIO THERAPY

Time : Three hours

Maximum : 100 marks

Answer ALL questions.

1. Give the pathology and diagnostic work up of a case of Ewing's Sarcoma of the Tibia. Mention the treatment in details along with the results. (25)
2. Discuss the pathology and clinical staging of Retinoblastoma. Describe the role of radiotherapy in its management. (25)
3. Write briefly on :
 - (a) Conformal radiation therapy
 - (b) Use of radiotherapy for benign conditions
 - (c) Adjuvant and neoadjuvant chemotherapy in carcinoma breast
 - (d) Organ preservation
 - (e) WHO step ladder for cancer pain. (5 × 10 = 50)

October-1999

[KA 155]

Sub. Code : 2037

M.D. DEGREE EXAMINATION

(Revised Regulations)

Branch IX — Radiotherapy

Part II — Final

**Paper III — CANCER CHEMOTHERAPY AND
RECENT DEVELOPMENT IN CLINICAL ONCOLOGY
AND RADIO THERAPY**

Time : Three hours

Maximum : 100 marks

Answer ALL questions.

1. Discuss the prognostic factors in Carcinoma Bronchus. Describe the current multi modality management of small cell anaplastic carcinoma of lung. (25)
2. What is the work up for staging of Hodgkin's Disease? Discuss the role of chemotherapy and radio therapy in Mixed Cellularity type of Hodgkin's disease Stage II B. (25)
3. Write briefly on : (5 × 10 = 50)
 - (a) Biological Response Modifiers
 - (b) The transition from 2-dimensional to 3-dimensional treatment planning in radiotherapy
 - (c) All-trans retinoic acid (ATRA)
 - (d) Cancer Screening
 - (e) Stereotactic radiosurgery.

April-2000

[KB 155]

Sub. Code : 2052

M.D. DEGREE EXAMINATION.

(Revised Regulations)

Branch IX — Radiotherapy

Part II — Final

Paper III — CANCER CHEMOTHERAPY AND
RECENT DEVELOPMENTS IN CLINICAL
ONCOLOGY AND RADIO THERAPY

Time : Three hours

Maximum : 100 marks

Answer ALL questions.

1. Discuss the diagnostic workup, staging, pathology, prognostic factors, therapeutic considerations and management of Rhabdomyosarcoma. (25)
2. Discuss the rationale, selection and process of three dimensional conformal radiation therapy. Add a note on the current research in this direction. (25)
3. Write briefly on :
 - (a) Chemo prevention
 - (b) Management of intractable pain
 - (c) Management of glottic carcinoma in-situ
 - (d) Stereotactic irradiation
 - (e) Photodynamic therapy. (5 × 10 = 50)

October-2000

[KC 155]

Sub. Code : 2052

M.D. DEGREE EXAMINATION.

Branch IX — Radiotherapy

(Revised Regulations)

Part II — Final

**Paper III — CANCER CHEMOTHERAPY AND
RECENT DEVELOPMENTS IN CLINICAL
ONCOLOGY AND RADIO THERAPY**

Time : Three hours

Maximum : 100 marks

1. How will you evaluate a treatment plan in Radiotherapy? What is the role of 3-D treatment planning in clinical radiotherapy? (25)
2. Discuss the recent advances in management of osteosarcoma. (25)
3. Write briefly on : (5 × 10 = 50)
 - (a) Intensity Modulated Radiotherapy.
 - (b) Intra operative Radiotherapy.
 - (c) Pulsed high dose rate brachytherapy.
 - (d) Hormone therapy in cancer.
 - (e) Tumour lysis syndrome.